loading page

Techno-economic analysis of semicontinuous bioreactor production of biopharmaceuticals in transgenic rice cell suspension cultures
  • +2
  • Jasmine Corbin,
  • Matthew McNulty,
  • Kantharakorn Macharoen,
  • Karen McDonald,
  • Somen Nandi
Jasmine Corbin
University of California Davis
Author Profile
Matthew McNulty
University of California, Davis
Author Profile
Kantharakorn Macharoen
University of California Davis
Author Profile
Karen McDonald
University of California, Davis
Author Profile
Somen Nandi
University of California, Davis
Author Profile

Peer review status:UNDER REVIEW

22 Apr 2020Submitted to Biotechnology and Bioengineering
24 Apr 2020Submission Checks Completed
24 Apr 2020Assigned to Editor
27 Apr 2020Reviewer(s) Assigned
15 May 2020Editorial Decision: Revise Major
15 May 2020Review(s) Completed, Editorial Evaluation Pending
06 Jun 20201st Revision Received
06 Jun 2020Submission Checks Completed
06 Jun 2020Assigned to Editor
22 Jun 2020Editorial Decision: Accept
22 Jun 2020Review(s) Completed, Editorial Evaluation Pending

Abstract

Biopharmaceutical protein production using transgenic plant cell bioreactor processes offers advantages over microbial and mammalian cell culture platforms due to the ability to produce complex biologics, use of simple chemically-defined, animal component-free media, robustness of host cells, and biosafety. A disadvantage of plant cells from a traditional batch bioprocessing perspective is their slow growth rate which has motivated us to develop semicontinuous and/or perfusion processes. Although the economic benefits of plant cell culture bioprocesses are often mentioned in the literature, to our knowledge no rigorous techno-economic models or analyses have been published. Here we present techno-economic models in SuperPro Designer® for the large-scale production of recombinant butyrylcholinesterase (BChE), a prophylactic/therapeutic bioscavenger against organophosphate nerve agent poisoning, in inducible transgenic rice cell suspension cultures. The base facility designed to produce 25 kg BChE per year utilizing two-stage semicontinuous bioreactor operation manufactures a single 400 mg dose of BChE for $263. Semicontinuous operation scenarios result in 4-11% reduction over traditional two-stage batch operation scenarios. In addition to providing a simulation tool that will be useful to the plant-made pharmaceutical community, the model also provides a computational framework that can be used for other semicontinuous or batch bioreactor-based processes.